Investment Summary

Hikma Pharmaceuticals PLC is a global multinational pharmaceutical company with a differentiated combination of injectables Leadership in the United States, a high-quality generics Business and a leading branded pharmaceuticals Franchise across the Middle East and North Africa. The company has consistently demonstrated disciplined execution, strong cash generation and Shareholder-friendly Capital returns. With improving fundamentals across all three core businesses, a robust pipeline, growing Leverage/">Operating Leverage and a still-attractive valuation, Hikma offers investors a balanced way to invest in specialty pharmaceuticals across both developed and emerging markets. We rate the shares a Buy.

Business Overview

Hikma is headquartered in London, with a primary listing on the London Stock Exchange as a constituent of the FTSE 250. Operations are organised around three business segments. The Injectables business is a leading supplier of generic injectable medicines in North America, Europe and the Middle East, including a broad range of oncology, anaesthetics, anti-infectives, cardiovascular and emergency medicines. The Generics business produces oral solid dose and other generic products for the US market, with a focus on differentiated formulations and complex products. The Branded business commercialises a portfolio of in-licensed and proprietary medicines across the Middle East and North Africa region.

The company operates more than 30 Manufacturing plants across the United States, Europe, the Middle East and North Africa, supporting both internal Demand and selected contract manufacturing arrangements. Hikma supplies more than 100 countries with approximately 800 products.

Sector Backdrop

The global pharmaceutical sector is benefiting from rising healthcare demand, ageing populations, expanding access to essential medicines and growing emphasis on Supply security. The generic injectable category is particularly resilient, with strong barriers to entry due to complex manufacturing requirements, regulatory scrutiny and the need for hospital-grade quality. Hospital and clinical buyers prioritise reliable supply, quality and breadth of portfolio, all of which favour established players with deep manufacturing networks. The US oral generics market faces structural pricing pressure, but companies with differentiated complex formulations, supply reliability and lean cost structures can maintain attractive margins. In the Middle East and North Africa, healthcare spending continues to grow at well above developed-market averages, supported by demographic growth, rising incomes, increasing chronic disease burden and government investment in healthcare infrastructure. Hikma is exceptionally well positioned across all of these segments.

Investment Thesis

There are several pillars to our positive view on Hikma. First, the Injectables business is one of the strongest franchises of its kind globally, with leadership positions in the US generic injectables market and a steadily expanding portfolio of complex and specialty injectables. Pricing dynamics in injectables remain more stable than in oral generics, supporting Margin durability. Second, the Generics business has been repositioned around complex products and value-added formulations, supporting more stable returns. Third, the Branded business is one of the largest providers of pharmaceuticals across the Middle East and North Africa region, benefiting from strong commercial relationships, local manufacturing and a portfolio of in-licensed and proprietary brands. Fourth, the company has a strong record of disciplined capital allocation, with a long history of progressive Dividend payments and selective M&A. Fifth, the Balance Sheet is conservative, providing flexibility for further investment. Together, these elements support resilient Earnings growth and attractive total returns over multiple years.

Growth Drivers

Injectables growth is being driven by an expanding portfolio of complex generic injectables, Biosimilars distribution arrangements, partnerships for novel injectable products and the ongoing investment in US, European and emerging market commercial capabilities. New launches in oncology supportive care, anaesthetics, anti-infectives and emergency medicine continue to broaden the offering. The Acquisition and integration of selected speciality injectable Assets has provided incremental growth. In the Generics business, complex products such as inhalation, transdermal and modified-release formulations are providing more defensible profit pools than commoditised oral tablets. New product approvals supported by Hikma's regulatory team continue to flow into the portfolio.

In Branded, growth is being supported by a combination of new product launches, in-licensing of innovative products from multinational partners, demographic-driven Volume growth and continued investment in commercial capability across Saudi Arabia, Egypt, Algeria, Morocco, the United Arab Emirates and other markets. Local manufacturing, regulatory expertise and deep relationships with healthcare professionals and government health systems remain key differentiators.

Financial Performance

Hikma has delivered a consistent track record of Revenue and earnings growth, with the Diversification across Injectables, Generics and Branded providing resilience through market cycles. Group revenues have grown at high single-digit rates on a constant-currency basis in recent periods, supported by injectables strength, recovery in branded markets and steady new product flow. Core operating margins are typically in the high teens to low 20s range, with strong cash conversion supporting reinvestment, dividend growth and selective M&A. Net Debt remains modest relative to EBITDA, providing flexibility to pursue value-creating opportunities while maintaining an investment-grade Credit profile. Management has set medium-term guidance for continued revenue and earnings growth, with a particular focus on building the Injectables franchise and continuing to expand in Branded markets.

Pipeline and Product Outlook

Hikma maintains a strong development pipeline across all three businesses. In Injectables, the pipeline includes complex generics, novel specialty injectables developed via partnerships, biosimilars distribution rights and new presentations of existing products. In Generics, the pipeline focuses on complex formulations, including inhaled products, transdermal patches, hormonal products and oral modified-release formulations. In Branded, the pipeline includes in-licensed branded medicines covering cardiovascular, metabolic, oncology, women's health, central nervous system and pain management, alongside locally developed products targeting regional disease prevalence. The company's strategy of combining internal R&D capability with selective licensing and partnerships supports a steady flow of new product launches, reducing reliance on any single asset and supporting longer-term durability.

Commercialisation Outlook

Commercialisation in Injectables is centred on hospital and clinic relationships, group purchasing organisations and integrated delivery networks. Hikma's Customer Service, supply reliability and breadth of portfolio are core competitive strengths. In Generics, channel relationships with wholesalers, retail pharmacy chains and managed care organisations support steady volume flow. In Branded markets, Hikma's commercial footprint includes hundreds of medical representatives, deep relationships with hospitals, physicians and pharmacists, and direct engagement with government health authorities. The company's dual capability as a manufacturer and a commercial partner gives it leverage across the value chain. Continued investment in Digital Marketing, real-world evidence, key opinion leader programmes and patient education is supporting prescription growth and Brand Equity.

Dividend and Capital Returns

Hikma maintains a clearly articulated progressive dividend policy and has a long record of increasing distributions year on year. The dividend is comfortably covered by free Cash Flow, with the Payout Ratio leaving room for both reinvestment and selective bolt-on M&A. Special dividends and share Buybacks have been used at various points to return surplus capital when leverage targets allow. For income-oriented investors, Hikma offers a combination of Yield and growth that is attractive within the global specialty pharmaceutical universe. The founding family retains a meaningful equity stake, which aligns interests with long-term shareholders and supports the company's conservative balance sheet philosophy and continued emphasis on disciplined growth.

Valuation Perspective

Hikma trades at a valuation that is below the broader specialty pharmaceutical peer group on forward price-to-earnings and EV/EBITDA metrics, despite its track record of resilient growth, strong cash conversion and shareholder returns. The discount reflects a combination of geographic mix, currency exposure across emerging markets and somewhat limited investor familiarity with the Middle East and North Africa branded business. We believe the current valuation provides an attractive entry point, with potential for multiple re-rating as the company continues to demonstrate the durability of its earnings and the strength of its Injectables franchise. Combined with an attractive Dividend Yield, total return potential is favourable.

Key Risks

Risks include US generic pricing dynamics, supply chain reliability across complex injectable products, regulatory inspection outcomes at manufacturing sites, currency Volatility, geopolitical uncertainty across Middle East and North Africa markets, and execution of pipeline launches. Branded markets are sensitive to government healthcare budgets, foreign exchange devaluations and Subsidy reform. Litigation related to historical product matters remains a Tail risk for the industry. Competitive intensity from international generic and specialty companies continues to require differentiated portfolio choices and operational execution.

Sustainability and ESG

Hikma's sustainability framework focuses on healthier communities, healthier planet, healthier business and healthier people. The company is investing in reducing greenhouse gas emissions, water use and waste, supporting access programmes for essential medicines, particularly across emerging markets, and continuing to strengthen workplace diversity and inclusion. Strong governance, ethical compliance and transparent reporting support investor confidence. The company's contribution to medicine access in emerging markets is particularly relevant within an ESG framework focused on the United Nations Sustainable Development Goals.

Operational Excellence and Manufacturing Strength

Hikma's vertically integrated manufacturing network provides a structural cost and supply advantage. With more than 30 plants spanning the United States, Europe, the Middle East and North Africa, the company can flex production locally, optimise inventory positioning, manage regulatory inspection cycles across jurisdictions and supply both branded and generic products with high reliability. Significant investment has been directed to manufacturing modernisation, automation, energy efficiency and quality systems. Hikma's track record of regulatory inspections, including FDA approvals for complex injectable products, is a critical commercial asset that underpins customer trust. Continued investment in capacity expansion, automation and digitalisation supports both growth and ongoing margin improvement.

Operational excellence extends beyond manufacturing. Hikma has invested in continuous improvement programmes across its commercial, regulatory, supply chain and corporate functions. Lean manufacturing, integrated planning and demand management tools, advanced analytics and digital workflow technologies are being deployed to enhance productivity. The company has also been integrating new sites and product portfolios from recent acquisitions effectively, demonstrating discipline in integration execution. This operational rigour underpins the consistent financial track record that has differentiated Hikma over many years.

Strategic Acquisitions and Partnerships

Hikma's M&A approach has been disciplined and value-accretive. Recent transactions have augmented the Injectables portfolio with specialty assets, added complex generic capabilities and broadened presence in adjacent specialty areas. Partnerships with originator companies for branded in-licensed products provide access to differentiated medicines that complement the proprietary portfolio. The combination of internal R&D, licensing arrangements and selective M&A supports a steady flow of new products without over-reliance on any single channel. Management has consistently emphasised return on invested capital discipline, conservative leverage and a focus on integration capability when evaluating opportunities, an approach that we believe will continue to deliver value over time.

Conclusion: Why We Rate Hikma a Buy

Hikma combines an industry-leading injectables franchise, a focused generics business, and a leading branded portfolio across the Middle East and North Africa, supported by disciplined capital allocation, a strong balance sheet and a clear track record of shareholder returns. With supportive long-term industry trends, robust pipelines and an attractive valuation, the shares offer a balanced combination of resilient earnings growth and dividend appeal. We therefore assign Hikma Pharmaceuticals PLC a Buy rating, viewing the stock as a well-priced way to capture global specialty pharmaceutical demand. The diversified business model, robust manufacturing footprint and consistent execution should support continued outperformance versus less diversified specialty pharmaceutical peers over the medium term.